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Abstract
Background: Alzheimers disease is common and debilitating, and diabetes is a widely documented risk factor
for the development of Alzheimers disease. Given that Alzheimers disease and diabetes are two extremely
common and comorbid conditions in geriatric populations that greatly affect quality of life, it follows that
treatment and prevention of both pathologies be exhaustively investigated. This is especially evident, as there
is no existing medication that prevents or reverses the pathogenesis of Alzheimers disease. Pioglitazone, a
peroxisome proliferator-activated receptor gamma agonists of the thiazolidinedione drug class, acts by up-
regulating gene expression cell receptors that improve insulin sensitivity at target tissue. This drug also has the
salutary effect of improving patient lipid profiles and acting as an anti-inflammatory agent. Research is
evolving that suggests that pioglitazone may play a role in preventing the onset of Alzheimers disease in non-
insulin dependent diabetic patients. Moreover, it has also been identified as possibly improving cognition in
patients with existing mild Alzheimers disease. The purpose this systematic review is to revisit research that
has been completed on pioglitazone regarding its efficacy treating mild cognitive impairment caused by
Alzheimers disease as well as its possible role in preventing the onset of Alzheimers disease in diabetic
patients.
Method: An exhaustive search using MEDLINE-Ovid, Web of Science, and Google Scholar was performed
using keywords pioglitazone and dementia. Studies found were screened with eligibility criteria and analyzed
for quality with GRADE. Clinical trials included two pilot, randomized control trials published in 2011
measuring piogtliazone’s use to treat mild cognitive impairment caused by Alzheimers disease. A retrospective
observational study measuring pioglitazone’s preventative effect delaying or preventing the onset of
Alzheimers disease was also included; this study has not yet been published, but has been accepted for
publication and undergone full peer review.
Results: Three studies were included in this systematic review, meeting the eligibility criteria. One RCT
looked at 42 patients with NIDDM and mild Alzheimers, showing statistically significant improvement in
cognitive function with six months of treatment with pioglitazone. Another RCT looked at 28 patients
without diabetes and with mild Alzheimers disease that found no significant improvement in cognition with
18 months of treatment with pioglitazone. Finally, a retrospective observational study demonstrated a 47%
risk reduction in the development of Alzheimers disease when patients were treated with pioglitazone for
greater than or equal to 8 quartiles (when compared to diabetics not receiving pioglitazone).
Conclusion: It is thought that pioglitazone may improve cognition and delay the onset of Alzheimers due to
its multiple positive benefits including increasing insulin sensitivity, improving lipid profiles, and acting as an
anti-inflammatory agent. While the quality of evidence that is currently available is not enough to suggest the
use of pioglitazone to treat mild cognitive impairment caused by Alzheimers disease, there is compelling data
to suggest its use as a preventative modality possibly delaying the onset of Alzheimers disease in diabetic
patients. This is an evolving area of research, and larger, double-blinded randomized control trials are needed
to elucidate pioglitazone’s efficacy. If found to be efficacious, pioglitazone, a drug that is widely available and
relatively safe to take, could help to uncouple the pathogenesis of two major pervasive and life altering disease
processes: diabetes and Alzheimers disease.
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|| Abstract || 
 
Background: Alzheimers disease is common and debilitating, and diabetes is a widely documented risk factor for 
the development of Alzheimers disease. Given that Alzheimers disease and diabetes are two extremely common and 
comorbid conditions in geriatric populations that greatly affect quality of life, it follows that treatment and 
prevention of both pathologies be exhaustively investigated. This is especially evident, as there is no existing 
medication that prevents or reverses the pathogenesis of Alzheimers disease. Pioglitazone, a peroxisome 
proliferator-activated receptor gamma agonists of the thiazolidinedione drug class, acts by up-regulating gene 
expression cell receptors that improve insulin sensitivity at target tissue. This drug also has the salutary effect of 
improving patient lipid profiles and acting as an anti-inflammatory agent. Research is evolving that suggests that 
pioglitazone may play a role in preventing the onset of Alzheimers disease in non-insulin dependent diabetic 
patients. Moreover, it has also been identified as possibly improving cognition in patients with existing mild 
Alzheimers disease. The purpose this systematic review is to revisit research that has been completed on 
pioglitazone regarding its efficacy treating mild cognitive impairment caused by Alzheimers disease as well as its 
possible role in preventing the onset of Alzheimers disease in diabetic patients.  
 
Method:  An exhaustive search using MEDLINE-Ovid, Web of Science, and Google Scholar was performed using 
keywords pioglitazone and dementia. Studies found were screened with eligibility criteria and analyzed for quality 
with GRADE. Clinical trials included two pilot, randomized control trials published in 2011 measuring 
piogtliazone’s use to treat mild cognitive impairment caused by Alzheimers disease. A retrospective observational 
study measuring pioglitazone’s preventative effect delaying or preventing the onset of Alzheimers disease was also 
included; this study has not yet been published, but has been accepted for publication and undergone full peer 
review. 
 
Results: Three studies were included in this systematic review, meeting the eligibility criteria. One RCT looked at 
42 patients with NIDDM and mild Alzheimers, showing statistically significant improvement in cognitive function 
with six months of treatment with pioglitazone. Another RCT looked at 28 patients without diabetes and with mild 
Alzheimers disease that found no significant improvement in cognition with 18 months of treatment with 
pioglitazone. Finally, a retrospective observational study demonstrated a 47% risk reduction in the development of 
Alzheimers disease when patients were treated with pioglitazone for greater than or equal to 8 quartiles (when 
compared to diabetics not receiving pioglitazone).  
 
Conclusion:  It is thought that pioglitazone may improve cognition and delay the onset of Alzheimers due to its 
multiple positive benefits including increasing insulin sensitivity, improving lipid profiles, and acting as an anti-
inflammatory agent. While the quality of evidence that is currently available is not enough to suggest the use of 
pioglitazone to treat mild cognitive impairment caused by Alzheimers disease, there is compelling data to suggest its 
use as a preventative modality possibly delaying the onset of Alzheimers disease in diabetic patients. This is an 
evolving area of research, and larger, double-blinded randomized control trials are needed to elucidate 
pioglitazone’s efficacy. If found to be efficacious, pioglitazone, a drug that is widely available and relatively safe to 
take, could help to uncouple the pathogenesis of two major pervasive and life altering disease processes: diabetes 
and Alzheimers disease.  
 
Keywords: Pioglitazone, dementia 
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Pioglitazone and Alzheimers Disease, a Possible Treatment and Preventative 
Modality 
 
 
 
BACKGROUND 
The Alzheimers Association reported in 2014 that one in nine people age 65 and older 
has Alzheimers disease.1 Cheng et al2 demonstrated in a large meta-analysis that across multiple 
studies, diabetes mellitus increased the risk for developing any type of dementia including mild 
cognitive impairment and Alzheimers disease (AD). Specifically, there has been evidence that 
suggests insulin deregulation and resistance may play a role in the multifactorial nature of 
dementia. Insulin resistance and hyperglycemia cause oxidative stress, worsen lipid profiles, and 
recruit pro-inflammatory markers to brain tissue resulting in further damage that encourage the 
pathogenesis of Alzheimers.3 Thus, diabetes is widely recognized as a significant risk factor for 
the development of dementia. 
Given that Alzheimers disease and diabetes are two extremely common and comorbid 
conditions in the geriatric population affecting quality of life, it follows that treatment and 
prevention of both pathologies be exhaustively investigated. There exist several medications that 
improve cognition in patients with Alzheimers disease and dementia such as cholinesterase 
inhibitors (e.g., donepezil and galantamine), and N-methyl-D-aspartate antagonists (e.g., 
memantine); however, no medication exists that slows or prevents the progression of the disease 
process.1,3 As such, prevention and treatment of Alzheimers and dementia is an evolving and 
necessary field of study, including management of risk factors and comorbid conditions such as 
diabetes. However, it has been found that tight control of serum glucose with metformin alone in 
non-insulin dependent diabetics may actually increased patient risk for development of 
Alzheimers disease.4 
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In the last decade, research has been done that suggests that the thiazolidinedione drug 
class (e.g., rosiglitazone and pioglitazone) may delay onset and improve cognition in patients 
with Alzheimers due to its action improving insulin sensitivity on brain tissue, its salutary effects 
improving patient lipid-profiles, and acting as an anti-inflammatory agent. Initial research 
focused on rosiglitazone, which showed mixed results as a treatment modality; however, 
rosiglitazone has since been given a Food and Drug Association (FDA) black box warning for 
myocardial infarction and thus is less readily prescribed – and for this reason, it is less likely to 
be studied.5  
Because rosiglitazone received this significant black box warning, the research focus has 
shifted to pioglitazone. In a mouse model study, Searcy et al6 found that after four months of 
treatment with pioglitazone, mice had improved learning, reduced serum cholesterol levels, 
decreased hippocampal amyloid-beta and tau deposits, and improved memory plasticity. The 
purpose of this systematic review is to revisit research that has been completed on pioglitazone 
regarding its efficacy when used to treat mild Alzheimers as well as its potential preventative 
effects postponing the onset of mild cognitive impairment (MCI) due to AD.  
METHODS 
An exhaustive literature search using MEDLINE-Ovid, Web of Science, and Google 
Scholar was conducted. The following search terms were used: pioglitazone, thiazolidinedione, 
dementia, and Alzheimers disease. Terms were then narrowed to pioglitazone and dementia. 
Additionally, the bibliographies of relevant articles were used to bring forth any other studies 
and background information. Included were human studies, studies written in English, studies 
with relevant primary outcomes, and studies with measurable outcomes. Excluded studies were 
articles, conferences, and posters that did not provide data regarding treatment effect.  
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RESULTS 
This searching method yielded 40 articles for review. After screening for relevant articles 
that met the aforementioned eligibility criteria, there were a total of three articles. Articles found 
were two randomized controlled trials7,8 measuring pioglitazone’s use as a treatment for mild 
cognitive impairment in mild Alzheimers disease, and one retrospective observational 
investigation9 measuring pioglitazone’s effect as a preventative tool delaying Alzheimers disease 
in diabetic patients. This last study9 has not yet been published but has been accepted for 
publication and undergone full peer review. Moreover, a large, double-blind random control trial 
called the TOMORROW study10 is currently being conducted by Takeda Development Center 
Americas, Inc., testing the use of pioglitazone as a preventative measure in delaying the onset of 
mild cognitive impairment due to Alzheimers as well as the efficacy of using genetic markers to 
predict Alzheimers. Included articles were given a GRADE profile (Table 1). 
Sato et al 
In this prospective randomized, open-controlled pilot study7 published in 2011, Sato et al 
attempt to measure the efficacy using pioglitazone to improve cognition in non-insulin 
dependent, type II diabetic patients with a Clinical Dementia Rating score of 0.5-1 (i.e., mild 
Alzheimers disease). The primary outcome relevant to this research paper was improvement on 
mini-mental state examination (MMSE); Alzheimers Disease Assessment Scale-Cognitive 
Subscale, a Japanese version (ADAS-Jcog); as well as Wechsler Memory Scale – Revised 
(WMS-R) logical memory I. Cognition was tested at six months of treatment. Several other 
endpoints were considered at six months of treatment including fasting plasma glucose, fasting 
immune-reactive insulin (FIRI), and homeostasis model assessment ratio (HOMA-R). 
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Researchers also measured the effect pioglitazone has on cerebral perfusion (rCBF) measured by 
SPECT MRA studies.7 
The study enrolled 42 eligible patients from the Memory Clinic at Tokyo Medical 
University Hospital. Included participants were diagnosed with Alzheimers disease via National 
Institute of Neurological and communicative Disorders and Stroke-The Alzheimers Disease and 
Related Disorders Association criteria and met standard criteria for a diagnosis of diabetes.  
Exclusion criteria included evidence of complicating neurological and psychological 
disorders, including depression and anxiety qualified as causing memory impairment, or use of 
medications such as neuroleptics, benzodiazepines, and antidepressants. Moreover, significant 
morbidity (cancer, chronic renal disease, heart failure, or uncontrolled insulin dependent 
diabetes) was also used as an exclusionary marker. Authors note that patients taking the 
cholinesterase inhibitor donepezil were included in the study if treatment had been stable for six 
months prior to the start date of the study and did not fluctuate during the study. Enrolled 
patients were randomized into prognostically similar groups: treatment with pioglitazone 15-
30mg per day (n=21) or control (n=21). Of note, this is an open-label study design and 
participants were aware of designation to control group, however designation was provided via 
sealed envelope method for one-sided blinding.7 
MMSE, ADAS-Jcog, and WMS-R logical memory I scores were recorded at baseline and 
at six months of treatment by a psychometrist blinded to the clinical data. Researchers found that 
MMSE, ADAS-Jcog and WMS-R logical memory I scores improved with statistical significance 
in treatment with pioglitazone group compared to scores recorded in control group. Moreover, 
ADAS-Jcog scores worsened for control groups over the duration of the study (Table 2). 
Interestingly, researchers found that rCBF deficits in the parietal lobe were improved after six 
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months treatment with pioglitazone; perfusion deficits in the posterior cortices and parietal lobe 
are often used as a radiological marker for the diagnosis of Alzheimers disease. There was no 
loss to follow up during this clinical trial.7 
 Due to the limitations of this study, and the nature of the measuring neurophysiological 
performance without a clear division or binary between no change and cognition improvement, 
an event rate was not calculated. Moreover, researchers only included the average change in 
neuropsychological scores of the entire treatment (n=21) and control group (n=21) without 
including raw data to provide further calculations such as NNT, RR, RRR, etc. Sato et al7 
acknowledge that the study has inherent flaws including incomplete blinding and small sample 
size. However, because cognitive function was found to be significantly improved by 
pioglitazone use in the treatment group, this study necessitates that a larger, double-blinded RCT 
study be completed with similar endpoints measured.7 
Geldmacher et al  
 In this double-blinded, placebo controlled pilot clinical trial8 published in 2011, 
Geldmacher et al investigate the safety of using pioglitazone in treatment of patients with 
Alzheimers disease. As a secondary endpoint, researchers also attempted to measure the efficacy 
of pioglitazone when used as treatment for mild Alzheimers via assessment with Clinical 
Dementia Rating (CDR), ADAS-cog, Neuropsychiatric Inventory (NPI), Alzheimers Disease 
Functional Assessment and Change Score, and Nurses’ Observation Scale for Geriatric Patients. 
For the purpose of this paper, ADAS-cog, CDR, and NPI scores are considered over other 
measurements.8  
 Twenty-nine participants were enrolled in this study that met the criteria established by 
the authors. Included participants were non-diabetic patients with a probable Alzheimers disease 
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diagnosed via National Institute of Neurological and communicative Disorders and Stroke-The 
Alzheimers Disease and Related Disorders Association criteria. Other inclusion criteria included 
a baseline MMSE score between 12-26 and a CDR score of 1-2 (i.e., patients mild Alzheimers 
disease). Patients with significant morbidity such as heart failure, diabetes mellitus requiring oral 
treatment or insulin treatment, as well as patients with neuropsychological disorders impacting 
baseline cognition, were excluded from the study.  
For this 18-month trial, enrolled patients were randomized and divided into two groups: 
treatment and control. Treatment group (n=14) received 15 mg pioglitazone titrated to 45 mg 
over the first three weeks of the study. Control group (n=14) received a matched placebo. All 
participants were also instructed to discontinue use of all vitamin supplementation including over 
the counter, and were given 200-IU vitamin E capsules to take daily due to known interaction 
between vitamin E and PPAR-gamma. Participants were evaluated every three months for a total 
of 18 months for health status as well as neuropsychological status. Researchers measured 
metabolic markers such as blood glucose, hemoglobin A1c, and liver function tests as well.8 
Regarding neuropsychological function, researchers found that there was no significant 
treatment effect (Table 2). However, Geldmacher et al acknowledge that it was predicted there 
would be no significant treatment effect due to small sample size. Moreover, the authors 
acknowledge that despite randomization, the average age of the treatment group was 74.9 years 
old compared to the average control age of 67.0 years old, a prognostic difference that may 
obscure any treatment effect. Of the 29 participants, a total of four patients were lost to follow 
up: two from treatment, and two from control group. Of note, the use of pioglitazone was well 
tolerated by participants with the exclusion of mild edema that did not prevent participants from 
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continuing on in the study. Mild edema was found in four treatment participants, versus zero 
suffering edema in the control group.  
Heneka et al  
 Heneka et al9 conducted a large-scale, retrospective observational analysis using 
accumulated data from 2004-2010 examining the association between pioglitazone and 
dementia. Specifically, researchers were expecting to find a decrease in incidence of dementia in 
diabetic patients taking pioglitazone compared to diabetic patients not taking pioglitazone. The 
authors examined the impact of several other covariates on dementia incidence as well including 
cerebrovascular disease, hypertension, ischemic heart disease, atrial fibrillation, and 
hypercholesterolemia.9 
 Observational data from 2004-2010 was collected from Germany’s largest public health 
insurance group Allgemeine Ortskrankenkassen (AOK). Data was screened for sex, age, ICD-10 
diagnosis codes, and filled prescription medications. Heneka et al9 included all patients that were 
60 years or old in 2004, and of that pool, all that had a new diagnosis of dementia from 2006-
2010. Dementia incidence was examined using ICD-10 codes as well as further validation of 
diagnosis to eliminate false positive diagnoses. Of the original pool, 13 177 patients developed 
dementia during the period of analysis and were found to have a valid diagnosis through rigorous 
analysis.9 
 Those that developed dementia were further subdivided into groups distinguished by the 
presence of diabetes, diabetes but no pioglitazone use, diabetes and pioglitazone use for less than 
eight quarters of a year, and having diabetes and receiving pioglitazone for equal to or greater 
than eight quarters of a year. Moreover, authors note that they corrected for the potentially 
complicating effects of concomitant use of other diabetes medications, mortality, exit from AOK 
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insurance use, or significant morbidity by using ICD-10 codes as well as rigorous methodology 
to exclude false positive diagnoses. Data was compared to findings of non-diabetic patients to 
measure treatment effect.9 
 Heneka et al used collected data to extrapolate hazard ratios for observed and predicted 
rates of dementia, again monitoring the effect of length of treatment (less than or greater than 8 
quarters of treatment with pioglitazone). Using hazard ratios, researchers further analyzed the 
data using a Cox proportional hazard model to examine relative risk of dementia with use of 
pioglitazone, rosiglitazone, metformin, and the before-mentioned covariates.  
 Researchers found that treatment with pioglitazone for greater than eight quarters greatly 
reduced the incidence of dementia in diabetic patients when compared to diabetics that did not 
receive pioglitazone. Incidence was adjusted to per 1000 person-years; diabetes with 
pioglitazone treatment for greater than eight quarters had an incidence of 7.41 (CI 4.21 - 13.04) 
compared to diabetics without treatment with pioglitazone with an incidence of 28.37 (CI 27.61 - 
29.15). Relative risk was subdivided into age groups to measure treatment effect (Table 3). 
Importantly, long-term use of pioglitazone was found to reduce risk of developing dementia in 
diabetic patients by 47% (RR=0.53) whereas diabetics not receiving pioglitazone treatment had a 
23% increase in dementia risk (RR=1.23) (Table 3).9 
DISCUSSION 
Animal studies have shown remarkable pharmacological effects using pioglitazone 
including improved learning, reduced serum cholesterol levels, decreased hippocampal amyloid-
beta and tau deposits, and improved memory plasticity.6 The research that has been done in 
clinical trials thus far is contradictory in that it has conflicting results; Sato et al7 found a 
statistically significant treatment effect whereas Geldmacher et al8 found no significant treatment 
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effect. However, this inconsistency may be related to the fact that in the Geldmacher et al8 study, 
there were remarkable prognostic differences between treatment and control groups. Specifically, 
in this study8, the treatment group was much older than control by an average of 7.9 years, and 
age is known to be the greatest risk factor for development of AD.1 The most compelling 
evidence exists with the Heneka et al study9, with a relative risk reduction of 47% of the 
development of AD in patients using pioglitazone for longer than an eighth quartile time span.  
What evidence does exist makes it abundantly clear that using pioglitazone for treatment 
and prevention of Alzheimers disease is a developing pharmacological option that requires a 
large, double-blinded clinical random control trial. Synthesizing the above information, there 
does not currently exist enough evidence to implement using pioglitazone as a treatment for MCI 
in mild Alzheimers disease due to significant limitations in quality of what research exists. 
As mentioned, there were major limitations in what literature was found. Both available 
randomized control studies were conducted on small sample sizes (n=42, n=29), and neither 
study included any raw data regarding patient demographics or individual responses to treatment. 
Because only the average of the total treatment effect (average change in cognitive function 
scores) was provided, no further analysis of data could be completed; it is impossible to 
determine if some individuals experienced a greater treatment effect when compared to others 
because only the average is provided. Moreover, Sato et al7  acknowledge that because their 
study is an open-label control study there is a potential for a placebo effect. Geldmacher et al8 
state that it was expected they would not observe a treatment effect due to the small sample size, 
noting also that the treatment and control group were not prognostically similar despite 
randomization. Heneka et al9 provided a larger scale epidemiological with compelling data 
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suggesting that pioglitazone has a very significant impact in delaying the onset of MCI caused by 
Alzheimers disease in patients with diabetes.  
Because there was a statistically significant treatment effect in the Sato et al study, the 
larger study of the two random control trial studies, and because of the large measured 
preventative effect measured by Heneka et al, this area of study warrants further analysis and 
further testing. The TOMORROW study10 is currently underway and may clarify the efficacy of 
using pioglitazone as a preventative medication for Alzheimers disease – which, coupled with 
the research provided in this systematic review, may unveil new measures that can be taken to 
prevent disease. 
Pioglitazone is a drug that is readily available and that was widely tolerated throughout 
the above studies, the primary adverse drug reaction being mild edema that was not significant 
enough to abscond participants from any studies. While at this stage, the research available may 
not be enough to suggest wide-scale use for non-diabetic patients, there is not significant harm 
associated with using pioglitazone that would prevent providers from considering its use 
concomitantly. Its use with other diabetes medications can tightly control serum glucose level 
with the possible added benefit of preventing or delaying the onset of Alzheimers disease in this 
at risk population.1 As a treatment for mild cognitive impairment caused by Alzheimers disease, 
not enough is known to suggest pioglitazone’s use.  
If pioglitazone were found to be a preventative drug option delaying the onset of 
Alzheimers disease and improving cognition in MCI Alzheimers patients, it would be a 
significant breakthrough in the field of Alzheimers disease research. Diabetes is a known risk 
factor for the development for Alzheimers disease and dementia, and both Alzheimers and 
diabetes are pervasive and life-altering pathologies that are extremely common. Uncoupling the 
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pathogenesis of these two diseases would save billions of industry dollars, countless years of life, 
and improve quality of life.  
CONCLUSION 
 Pioglitazone can be considered as an adjunct therapy in the treatment of NIDDM as it 
may have the benefit of delaying or preventing the onset of Alzheimers disease. The overall 
quality of evidence for pioglitazone’s use has significant limitation and is of low quality and with 
opposing findings, however this is an ongoing area of research and there is currently a large-
scale, double-blinded random control trial underway in the TOMORROW study. If found to be 
efficacious, pioglitazone may be used to uncouple the pathogenesis of two major, pervasive life 
altering diseases, diabetes and Alzheimers disease. This advancement would be a major 
breakthrough in Alzheimers disease research. 
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Table 1: Quality Assessment of Reviewed Articles 
Outcome 
Number 
of 
studies 
Study Designs 
Downgrade Criteria 
Upgrade 
Criteria 
Quality 
Limitation Indirectness Inconsistency Imprecision 
Publication 
bias 
Improved 
Cognition 
2 RCT Seriousa Not Serious Seriousb Seriousc Unlikely 
Significant 
response to 
therapyb 
Very 
Low 
Prevention 
of AD 
1 
Retrospective 
Observational 
Not 
Serious 
Not Serious Not Serious Not Serious Unlikely 
Very 
Large 
Magnitude 
of Effectd 
Moderate 
NOTES 
a. Lack of complete blinding in Sato et al7, prognostic difference between treatment and control groups in Geldmacher et al8 
b. Studies had conflicting results  
c. Small sample sizes 
d. Some evidence of a dose-response gradient 
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Table 2. A summary of measured cognitive changes in Sato et al7 and Geldmacher et al8  
 TREATMENT 
(n=21) 
CONTROL 
(n=21)  
Sato et al7  Baseline 
(SD) 
6 months 
treatment 
(SD) 
Baseline (SD) 6 months 
treatment (SD) 
 MMSE 22.1(3.5) 23.1(4.1) 21.9(3.4) 21.6(3.0) 
 ADAS-Jcog 15.5(5.9) 14.2(6.5) 15.3(4.7) 17.5(5.2) 
 WMS-LM1 6.5(4.1) 7.8(4.7) 5.7(3.2) 5.4(3.6) 
      
 TREATMENT 
(n=14) 
CONTROL 
(n=14) 
 
Geldmacher et al8  Baseline 
(SD) 
18 months 
Treatment 
(SD) 
Baseline (SD) 18 months 
treatment (SD) 
 ADAS-cog 21.79(7.3) 27.25(11.92) 20.2(9.5) 26.08(12.3) 
 CDR-SB 10.43(9.68) 6.75(8.55) 6.67(8.12) 10.85(7.84) 
 NPI  6.44(2.13) 8.92(4.15) 5.24(1.32) 7.58(3.24) 
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    Table 3. A summary of findings from Heneka et al9 study  
Variable Person-years 
(n=633 418) 
Subjects with 
dementia  
(n=13 177) 
Dementia incidence rate per 1000 person-
years 
 Number (percent) Number (percent) Rate 95% Confidence Interval 
No diabetes 443 559 (70.0) 7 845 (59.5) 17.69 17.30 - 18.08 
Diabetes without 
PIO* 
185 864 (29.3) 5 273 (40.0) 28.37 27.61 - 29.15 
Diabetes and PIO 
<8 qrts 
2 375 (0.4) 47 (0.4)  19.79 14.87 – 26.34 
Diabetes and PIO 
>=8qrts 
1 620 (0.3) 12 (0.1) 7.41 4.21 -13.04 
     
Variable Model 1 
Age 60+ 
Model 2 
Age 60-69 
Model 3 
Age 70-79 
Model 4 
Age 80+ 
 RR  95% CI RR 95% CI RR 95% CI RR 95% CI 
Diabetes and no 
PIO 
1.23 1.19-1.28 1.61 1.37-1.88 1.27 1.18-
1.36 
1.18 1.12-1.24 
Diabetes and PIO 
<8 
1.16 0.87-1.55 1.13 0.46-2.80 0.87 0.53-
1.44 
1.47 0.93-2.17 
PIO >=8 0.53 0.30-0.94 0.41 0.06-2.92 0.46 0.19-
1.10 
0.66 0.30-1.48 
*PIO = pioglitazone 
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